Clinical Trial Update: Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TBX-3400 in solid malignant tumors resistant or refractory to standard therapies (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumor Cancer

Drugs mentioned

• TBX-3400

Snippet

Sponsor: Taiga Biotechnologies, Inc. | Conditions: Cancer, Tumor, Solid | Phase 1, Phase 2 | Status: UNKNOWN